Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02207569 · ClinicalTrials.gov registry record · NA
Medtronic CoreValve Evolut R U.S. Clinical Study
A NA study of Aortic Stenosis, sponsored by Medtronic Cardiovascular.
- Completed
- Registry status
- NA
- Development phase
- 241
- Enrollment target
- 20
- Study locations
NCT02207569: Completed NA study of Aortic Stenosis, sponsored by Medtronic Cardiovascular.
NCT02207569 is a NA study of Aortic Stenosis that has completed, run by Medtronic Cardiovascular. The registered enrollment target is 241 participants, below the 1,353-participant average among 26 other Aortic Stenosis trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02207569, a NA study of Aortic Stenosis, has completed, sponsored by Medtronic Cardiovascular.
- COMPLETED
- Registry status
- NA
- Development phase
- 241 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study objectives are to assess the safety and efficacy of the CoreValve Evolut R transcatheter aortic valve replacement (TAVR) system in patients with severe symptomatic aortic stenosis are considered at high or extreme risk for surgical aortic valve replacement.
Primary Outcome
Percentage of patients that died by any cause at 30 days
Conditions Studied
Interventions
- DEVICE CoreValve Evolut R TAVR system
Study Locations (20)
New York
- New York Langone Medical Center - New York
- The Mount Sinai Medical Center - New York
- Columbia University Medical Center - New York
- St. Francis Hospital - Roslyn
Michigan
- University of Michigan Health Systems - Ann Arbor
- Detroit Medical Center Cardiovascular Institute - Detroit
- Spectrum Health - Grand Rapids
Pennsylvania
- University of Pittsburg Medical Center - Pittsburgh
- Pinnacle Health - Wormleysburg
Arizona
- Banner Good Samaritan Medical Center - Phoenix
California
- University of Southern California - Los Angeles
Connecticut
- Yale New Haven Hospital - New Haven
District of Columbia
- Washington Hospital Center/Medstar - Washington D.C.
Indiana
- St. Vincent Heart Center of Indiana/The Care Group, LLC - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 241 participants |
| Start Date | 2014-08 |
| Est. Completion | 2020-10-28 |
| Phase | NA |
What the finished NCT02207569 record still lists
NCT02207569 is an interventional study that assigns participants to a tested intervention. The registered 241 participants enrollment target is mid-sized for trials with a published cap, below the 1,353-participant average among 26 other Aortic Stenosis trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Aortic Stenosis appearing as the primary indexed condition, and to 1 intervention - of which CoreValve Evolut R TAVR system is the first listed.
NCT02207569 names 20 study sites across 14 states, led by New York, Michigan, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02207569 about?
NCT02207569 is a clinical study titled "Medtronic CoreValve Evolut R U.S. Clinical Study". The study objectives are to assess the safety and efficacy of the CoreValve Evolut R transcatheter aortic valve replacement (TAVR) system in patients with severe symptomatic aortic stenosis are considered at high or extreme risk for surgical aortic valve replacement.
What is the current status of trial NCT02207569?
This trial is currently completed. It is a NA study. The enrollment target is 241 participants. The study started on 2014-08. Estimated completion is 2020-10-28.
What conditions does trial NCT02207569 study?
This clinical trial studies the following conditions: Aortic Stenosis.
What interventions are being tested in trial NCT02207569?
The interventions under investigation include: CoreValve Evolut R TAVR system (DEVICE).
Who is sponsoring clinical trial NCT02207569?
This trial is sponsored by Medtronic Cardiovascular, which has 44 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02207569 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aortic Stenosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02207569's enrollment target sits among peer trials
241 13th of 26 higher than 14 of 26 other Aortic Stenosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Aortic Stenosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Correlation Between an Impedance Cardiography Test for Decompensation and the Development of Left Ventricular Replacement Fibrosis
RECRUITING · NA
-
Evaluating Infrasonic Hemodynography
RECRUITING · NA
-
Improved Outcomes With Pre-Procedure Shockwave IVL of Common Femoral Artery Access Site Prior to Large Bore Access and Pre-Closure
RECRUITING · NA
-
PARTNER 3 Trial - Aortic Valve-in-Valve
RECRUITING · NA
-
Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement
RECRUITING · NA
-
ProspeCtive, nOn-randoMized, MulticENter Clinical Evaluation of Edwards Pericardial Bioprostheses With a New Tissue Treatment Platform (COMMENCE)
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01189786 · 241 participants · NA
Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection
- NCT05050383 · 241 participants · NA
DISE: Phenotyping Obstruction Patterns
- NCT05683418 · 241 participants · Phase 1
A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors
- NCT07213791 · 241 participants · Phase 1
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia